Title of article :
PPAR agonists: multimodal drugs for the treatment of type-2 diabetes
Author/Authors :
Barbara Gross، نويسنده , , Bart Staels، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2006
Pages :
24
From page :
687
To page :
710
Abstract :
Patients with type-2 diabetes mellitus (T2DM) are considered to be at particularly high risk for cardiovascular disease. Over the last decade, the members of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors have emerged as valuable pharmacological targets whose activation can normalize metabolic dysfunctions and reduce some cardiovascular risk factors associated with T2DM. PPARα agonists, such as the fibrates, can correct dyslipidemia. PPARγ agonists, such as the thiazolidinediones, act as insulin sensitizers and improve insulin resistance in patients with T2DM. Because of restricted potency and certain side-effects of PPAR agonists, as well as the increasingly epidemic incidence of T2DM, there is a real need for the development of selective PPAR agonists with improved clinical efficacy. This chapter focuses on the PPAR agonists currently used in the clinic, as well as on the discovery and development of the next generation of PPAR agonists
Keywords :
insulin resistance , Nuclear receptor , PPAR , Lipid metabolism , Cardiovascular disease , type-2 diabetes , dual agonist , SPPARM , pan-PPAR agonist
Journal title :
Best Practice and Research Clinical Endocrinology and Metabolism
Serial Year :
2006
Journal title :
Best Practice and Research Clinical Endocrinology and Metabolism
Record number :
466090
Link To Document :
بازگشت